Keywords
Adolescents
Ovarian germ cell tumors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To present a case report of ovarian dysgerminoma in an adolescent treated in the public healthcare system of the Federal District, to analyze the survival of patients undergoing conservative surgical treatment, with focus on current evidence. Case details: A 17-year-old female patient presented to an emergency department in the Federal District with severe pelvic pain associated with progressive abdominal enlargement. Following investigation through imaging studies (ultrasonography and pelvic magnetic resonance imaging) and tumor markers, the patient underwent exploratory laparotomy with left salpingo-oophorectomy, with intraoperative capsular rupture. Histopathological and immunohistochemical diagnosis confirmed ovarian dysgerminoma, FIGO stage IC1. The patient was referred for surveillance without adjuvant chemotherapy and is currently under follow-up with tumor marker monitoring. Final considerations: Conservative surgery with surveillance without initial adjuvant therapy constitutes the standard approach for dysgerminoma stage IA-IC adolescents, allowing high survival rates and preservation of fertility comparable to the general population. Therapeutic decision-making should be individualized and multidisciplinary, considering staging, the desire for fertility preservation, and risk factors.
References
DANTKALE KS e AGRAWAL M. A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors. Cureus, 2024; 16(1): 52650.
DE MARIA F, et al. Malignant germ cells tumor of the ovary. J Gynecol Oncol, 2025; 36(3): 108.
ERGUN-LONGMIRE B e GREYDANUS DE. Ovarian tumors in the pediatric population: An update. Dis Mon, 2024; 70(6): 101691.
ESGO. EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY. Non-epithelial ovarian cancers in adolescents and young adults: pocket guidelines. ESGO, 2019. Disponível em: https ://guidelines.esgo .org. Acessado em: 02 de dezembro de 2025.
ESMO. EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018; 29(4): 1-18.
FEBRASGO. FEDERAÇÃO BRASILEIRA DAS ASSOCIAÇÕES DE GINECOLOGIA E OBSTETRÍCIA. Preservação da fertilidade em mulheres com câncer ginecológico. 3ª ed. São Paulo: FEBRASGO, 2025. (Protocolos FEBRASGO, Ginecologia, no. 37). iv, 17p. Disponível em: https ://www.febrasgo.org.br/pt/gin ecologia/category/pres ervacao-da-fertilidade-em-mulheres-com-cancer-ginecologico. Acessado em: 02 de dezembro de 2025.
FEBRASGO. FEDERAÇÃO BRASILEIRA DAS ASSOCIAÇÕES DE GINECOLOGIA E OBSTETRÍCIA. Tumores ovarianos na adolescência. 3ª ed. São Paulo: FEBRASGO, 2025. (Protocolos FEBRASGO, Ginecologia, no. 33). iv, 26p. Disponível em: https ://www.febrasgo.org.br/pt/ginecologia/category/tumor es-ovarianos-na-adolesce ncia. Acessado em: 02 de dezembro de 2025.
GÖÇ G, et al. Spontaneous pregnancy after fertility-sparing surgery and adjuvant chemotherapy for advanced pure dysgerminoma: A case report. Clin Case Rep, 2024; 12(6): 9020.
LEDERMANN J, et al. ESGO-ESMO-ESP. Consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol, 2024; 35(3): 248-266.
MARGIOULA-SIARKOU C, et al. Therapeutic Management and Prognostic Factors for Ovarian Malignant Tumours in Adolescents: A Comprehensive Review of Current Guidelines. Diagnostics, 2023; 13(6): 1080.
MITRANOVICI MI, et al. Diagnosis and Management of Dysgerminomas with a Brief Summary of Primitive Germ Cell Tumors. Diagnostics, 2022; 12(12): 3105.
MORICE P, et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol, 2024; 25(11): 602-610.
MOURA AA, et al. Disgerminoma ovariano na gestação: relato de caso. Femina. 2022; 50(5): 316-20.
NCCN. NATIONAL COMPREHENSIVE CANCER NETWORK. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian Cancer. Version 3.2025. Fort Washington: NCCN, 2025. Disponível em: www.nccn.org. Acessado em: 02 de dezembro de 2025.
PILARSKA I, et al. What is new about germ cell ovarian tumors? Oncol Clin Pract, 2022; 18(2): 115–118.
RENZ M, et al. FIGO (International Federation of Gynecology and Obstetrics). Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. Int J Gynaecol Obstet, 2025; 171(1): 6-35.
SALHI H, et al. Pure dysgerminoma of the ovary: a study of 31 cases. Int J Reprod Contracept Obstet Gynecol, 2021; 10(8): 3197-3203.
VARLAS VN, et al. Fertility-sparing surgery: a hopeful strategy for young women with cancer. J Med Life, 2023; 16(7): 974-980.
XIE W, et al. Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the global burden of disease study 2021. Int J Surg, 2025.
YANG J, et al. Updates in the Management of Malignant Ovarian Germ Cell Tumors. O&G Open, 2025; 2(4): 95